
Nina Haagenrud Schultz
- Consultant; PhD
Publications 2023
New interest group for red blood cell disorders
Tidsskr Nor Laegeforen, 143 (3)
DOI 10.4045/tidsskr.22.0731, PubMed 36811425
Publications 2022
Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects
Vaccines (Basel), 10 (8)
DOI 10.3390/vaccines10081267, PubMed 36016155
In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study
J Cardiothorac Vasc Anesth, 36 (6), 1636-1644
DOI 10.1053/j.jvca.2022.01.038, PubMed 35272914
Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study
J Stroke Cerebrovasc Dis, 32 (1), 106860
DOI 10.1016/j.jstrokecerebrovasdis.2022.106860, PubMed 36403363
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease
Res Pract Thromb Haemost, 6 (7), e12814
DOI 10.1002/rth2.12814, PubMed 36284639
Publications 2021
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
Eur Heart J, 42 (39), 4064-4072
DOI 10.1093/eurheartj/ehab506, PubMed 34405870
Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study
Clin Appl Thromb Hemost, 27, 10760296211021156
DOI 10.1177/10760296211021156, PubMed 34060371
The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study
Res Pract Thromb Haemost, 5 (5), e12561
DOI 10.1002/rth2.12561, PubMed 34263107
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
N Engl J Med, 384 (22), 2124-2130
DOI 10.1056/NEJMoa2104882, PubMed 33835768
Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series
Front Neurol, 12, 721146
DOI 10.3389/fneur.2021.721146, PubMed 34393988
Publications 2019
The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Thromb Res, 177, 154-156
DOI 10.1016/j.thromres.2019.03.010, PubMed 30903875
Publications 2018
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
Platelets, 31 (1), 43-47
DOI 10.1080/09537104.2018.1557618, PubMed 30569801
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
J Med Case Rep, 12 (1), 138
DOI 10.1186/s13256-018-1660-9, PubMed 29764497
Publications 2017
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Thromb J, 15, 6
DOI 10.1186/s12959-017-0129-1, PubMed 28239301
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro
Res Pract Thromb Haemost, 1 (1), 49-56
DOI 10.1002/rth2.12015, PubMed 30046673